Bladder Cancer: Symptoms, Diagnosis, Stages and Treatment
By Mr Neil Haldar, Consultant Urological Surgeon — Buckinghamshire, Berkshire and London
Bladder cancer most commonly causes blood in the urine (haematuria), often without pain. Even a single episode of visible blood in the urine should be investigated, because bladder cancer can bleed intermittently and the urine may return completely to normal between episodes.
Most bladder cancers are found before they have invaded the muscle of the bladder. These non-muscle-invasive bladder cancers can usually be treated through the urethra using a procedure called TURBT, sometimes followed by chemotherapy or BCG treatment directly into the bladder.
Muscle-invasive bladder cancer requires more intensive treatment. Depending on the individual cancer and the patient’s fitness and priorities, treatment may involve systemic treatment followed by radical cystectomy, or bladder-preserving chemoradiotherapy.
Treatment for bladder cancer has changed considerably in recent years, particularly with the introduction of immunotherapy and antibody-drug conjugates for selected patients.
Key points about bladder cancer
- Blood in the urine is the most important warning sign.
- Bladder cancer bleeding is frequently painless and intermittent.
- Seeing blood only once does not make it safe to ignore.
- Around 10,900 bladder cancers are diagnosed in the UK each year.
- Smoking is the most important preventable risk factor and accounts for approximately 45% of UK bladder cancer cases.
- Most bladder cancers are non-muscle-invasive when diagnosed.
- TURBT is the key procedure used to remove visible early bladder cancer and establish its stage and grade.
- Higher-risk cancers may require treatment inside the bladder with BCG immunotherapy or intravesical chemotherapy.
- Muscle-invasive bladder cancer can often still be treated with curative intent.
- Treatment may involve systemic therapy and radical cystectomy or bladder-preserving chemoradiotherapy.
- Bladder cancer frequently recurs, making appropriate surveillance particularly important.
Cancer Research UK currently records approximately 10,900 new cases annually in the UK, with around 7,900 occurring in men and 3,000 in women. Around 45% of UK bladder cancers are attributed to smoking.
What is bladder cancer?
The bladder is a hollow muscular organ that stores urine.
Its inner surface is covered by a specialised waterproof lining called the urothelium. The same type of lining continues upwards through the ureters and into the collecting systems of the kidneys.
Most bladder cancers begin when cells within this urothelium start growing abnormally.
The commonest type is urothelial carcinoma, historically called transitional cell carcinoma.
Bladder tumours can grow in several different ways.
Some form small, frond-like or cauliflower-like growths that project into the bladder. These are called papillary tumours.
Others form a flatter abnormal area in the bladder lining. An important example is carcinoma in situ (CIS), which is a flat, high-grade form of bladder cancer.
Most importantly, some tumours begin to grow more deeply into the bladder wall.
This leads to the fundamental distinction in bladder cancer:
Non-muscle-invasive bladder cancer
The tumour remains within the inner layers of the bladder and has not invaded the bladder muscle.
Muscle-invasive bladder cancer
The tumour has grown into the bladder’s muscular wall.
This distinction is crucial because it largely determines the treatment required.
What are the symptoms of bladder cancer?
Blood in the urine — haematuria
Blood in the urine is the classic symptom of bladder cancer.
It may appear:
- bright red
- pink
- brown
- tea-coloured
- mixed throughout the urine
- occasionally as clots
The most important characteristic is that bladder cancer bleeding is often painless.
Patients understandably assume that something serious should hurt. Unfortunately, early bladder cancer frequently does not.
Another characteristic is that the bleeding may come and go.
You might see blood once and then have completely normal urine for several weeks.
That does not make the episode less important.
Intermittent bleeding is entirely compatible with bladder cancer.
I saw blood in my urine only once. Should I still be investigated?
Yes.
A single unexplained episode of visible haematuria in an adult deserves assessment.
It is particularly important if:
- you are over 45
- the bleeding was painless
- you smoke or previously smoked
- you have had previous occupational chemical exposure
- you have urinary symptoms without evidence of infection
- you have previously received pelvic radiotherapy
Most people investigated for haematuria will not ultimately have bladder cancer. However, the possibility is important enough that you should establish the cause rather than assume it.
Urinary frequency, urgency and discomfort
Bladder cancer can sometimes cause symptoms resembling infection or an overactive bladder, including:
- passing urine more frequently
- sudden urinary urgency
- burning or discomfort when passing urine
- pelvic discomfort
- persistent bladder irritation
These symptoms are particularly important when urine cultures repeatedly show no infection.
Carcinoma in situ can produce marked bladder irritation without necessarily causing obvious visible bleeding.
Repeated episodes of apparent “cystitis” with negative urine cultures therefore merit further investigation.
Symptoms of more advanced bladder cancer
Less commonly, advanced disease can cause:
- pain in the loin or flank from obstruction of a ureter
- unexplained weight loss
- persistent pelvic pain
- bone pain
- swelling of the legs
- fatigue or anaemia
These symptoms have many possible causes and do not automatically mean advanced cancer, but they require appropriate assessment.
When should blood in the urine be investigated urgently?
NICE recommends suspected-cancer referral for bladder cancer in people aged 45 or over with unexplained visible haematuria without urinary infection, or where visible haematuria persists or recurs following successful treatment of a urinary infection.
Urgent referral is also recommended in people aged 60 or over with unexplained non-visible haematuria accompanied by dysuria or a raised white-cell count.
These thresholds help guide NHS referral pathways.
They should not be interpreted as meaning that unexplained haematuria below these ages is automatically safe.
If you have seen blood in your urine, particularly if it was painless, seek medical assessment rather than waiting to see whether it happens again.
What causes bladder cancer?
There is rarely one single explanation for why an individual develops bladder cancer, but several important risk factors are known.
Smoking
Smoking is the most important preventable cause.
Chemicals contained in tobacco smoke enter the bloodstream, are filtered by the kidneys and become concentrated in urine.
The bladder lining is consequently exposed to these carcinogens whenever urine is stored in the bladder.
Cancer Research UK estimates that smoking causes approximately 45% of bladder cancers in the UK.
Stopping smoking is worthwhile even after a bladder cancer diagnosis.
Occupational exposure
Certain industrial chemicals, particularly aromatic amines used historically in manufacturing, are associated with bladder cancer.
Previous higher-risk occupations have included some work involving:
- dyes and pigments
- rubber manufacturing
- textiles
- leather
- printing
- painting
- industrial chemicals
The interval between exposure and cancer development can be several decades.
A detailed occupational history can therefore be relevant even if the exposure occurred many years ago.
Previous radiotherapy and chemotherapy
Previous radiotherapy to the pelvis can slightly increase the risk of developing a subsequent bladder cancer many years later.
The chemotherapy drug cyclophosphamide is also associated with an increased risk.
Chronic bladder irritation
Long-term irritation of the bladder can increase the risk of some types of bladder cancer.
Examples include:
- long-term indwelling catheters
- chronic bladder stones
- repeated infection and inflammation
- schistosomiasis
Schistosomiasis is particularly relevant in people who have lived in certain regions of Africa and the Middle East.
Age and sex
Bladder cancer becomes considerably more common with increasing age and is substantially more common in men than women.
One concern in women is that haematuria may initially be attributed to urinary infection or gynaecological bleeding.
Blood in the urine deserves proper assessment regardless of sex.
How is bladder cancer diagnosed?
The investigation usually involves a combination of:
- consultation and clinical history
- urine testing
- flexible cystoscopy
- imaging of the kidneys and urinary tract
- TURBT if a bladder tumour is identified
Urine tests
Urine is commonly checked for:
- blood
- infection
- abnormal cells
A urine culture helps establish whether infection is present.
Urine cytology examines cells shed into the urine. It can be particularly useful in detecting some high-grade tumours and carcinoma in situ.
A negative urine cytology result does not exclude bladder cancer.
What is a flexible cystoscopy?
Flexible cystoscopy is the key initial investigation for directly examining the inside of the bladder.
A thin, flexible telescope with a camera is gently passed through the urethra into the bladder.
The procedure is normally performed using local anaesthetic gel and takes only a few minutes.
It allows the urologist to examine the bladder lining directly and identify:
- bladder tumours
- suspicious red areas
- stones
- inflammation
- other structural abnormalities
Most patients tolerate flexible cystoscopy considerably better than they expected.
Mild burning during urination and a small amount of blood can occur afterwards and generally settle quickly.
Do I need a CT scan?
The kidneys and ureters also need consideration when investigating visible haematuria because urothelial cancer can arise elsewhere in the urinary tract.
A CT urogram gives detailed images of:
- kidneys
- ureters
- bladder
Ultrasound may be appropriate in some lower-risk circumstances or where CT contrast or radiation should be avoided.
The investigation chosen depends upon the patient’s age, symptoms, kidney function and overall risk profile.
What happens if a tumour is found?
If cystoscopy demonstrates a bladder tumour, the usual next step is transurethral resection of bladder tumour, or TURBT.
TURBT has two purposes:
1. To remove the visible tumour
and
2. To obtain tissue so a pathologist can establish exactly what type of cancer it is, how aggressive it appears and how deeply it has grown.
What is TURBT?
TURBT is usually performed under general or spinal anaesthesia.
A rigid telescope is passed through the urethra, so there is normally no external incision.
Instruments passed through the telescope remove the tumour.
A key part of the procedure is obtaining an adequate sample of the underlying bladder muscle, where appropriate.
This allows the pathologist to determine whether the cancer has invaded the muscular bladder wall.
That distinction can completely change subsequent treatment.
Enhanced cystoscopy
Some tumours—particularly carcinoma in situ—can be difficult to identify using conventional white-light cystoscopy alone.
Techniques that may improve detection include:
Photodynamic diagnosis — blue-light cystoscopy
A photosensitising agent is placed inside the bladder before cystoscopy. Abnormal tissue then fluoresces under blue light, helping identify areas that might otherwise be missed.
Narrow-band imaging
Filtered wavelengths of light make abnormal tumour blood vessels more conspicuous.
These techniques can be particularly useful in selected patients with high-risk or multifocal disease.
Will I need chemotherapy in the bladder after TURBT?
For appropriately selected patients with apparently low-risk disease, a single dose of intravesical chemotherapy may be administered soon after TURBT.
The medication is placed directly into the bladder through a catheter rather than being administered through the bloodstream.
Its purpose is to destroy tumour cells that may have been released during the procedure and reduce subsequent recurrence.
It is not appropriate where there is concern about bladder perforation or significant postoperative bleeding.
Understanding bladder cancer stage
The stage describes how deeply the tumour has grown.
Ta
A papillary tumour confined to the superficial bladder lining.
Tis — carcinoma in situ
A flat, high-grade cancer confined to the urothelium.
Although it has not invaded the muscle, CIS is biologically important and requires treatment.
T1
The tumour has grown into the connective tissue beneath the bladder lining but has not reached the muscle.
T2
The tumour has invaded bladder muscle.
T3
The tumour has extended through the muscle into surrounding tissue.
T4
The tumour has invaded neighbouring structures.
Lymph node involvement is described using N staging, while distant spread is described using M staging.
What is the difference between stage and grade?
These terms are sometimes confused.
Stage describes where the cancer has grown.
Grade describes how abnormal and aggressive the cancer cells appear under the microscope.
A small high-grade tumour can therefore be more concerning than a larger low-grade superficial tumour.
The combination of:
- stage
- grade
- tumour size
- number of tumours
- presence of carcinoma in situ
- previous recurrence
- pathological features
helps determine the risk of recurrence or progression.
Non-muscle-invasive bladder cancer
Stages Ta, T1 and carcinoma in situ are collectively referred to as non-muscle-invasive bladder cancer, or NMIBC.
Most patients diagnosed with bladder cancer fall into this category.
Treatment is determined by whether the cancer is considered:
- low risk
- intermediate risk
- high risk
- very high risk
Treatment of low-risk bladder cancer
For a small solitary low-grade tumour, treatment may consist of:
- complete TURBT
- immediate intravesical chemotherapy when appropriate
- follow-up cystoscopy
The risk of recurrence is significant, but the risk of progression to life-threatening invasive disease is usually low.
Surveillance remains important because bladder cancer has a tendency to recur.
Treatment of intermediate-risk bladder cancer
Intermediate-risk disease may include:
- recurrent low-grade tumours
- multiple tumours
- larger low-grade tumours
Treatment frequently involves a course of chemotherapy placed directly inside the bladder.
Mitomycin C is one commonly used drug.
Treatment is administered through a small catheter and is followed by scheduled cystoscopic surveillance.
Treatment of high-risk non-muscle-invasive bladder cancer
High-grade T1 cancer and carcinoma in situ require substantially more intensive management because their risk of recurrence and progression is greater.
Two particularly important treatment strategies are:
BCG immunotherapy
and, in selected very-high-risk circumstances,
Early radical cystectomy.
What is BCG treatment for bladder cancer?
BCG—Bacillus Calmette-Guérin—is a form of intravesical immunotherapy.
It is a weakened strain of Mycobacterium bovis, related to the organism used in the tuberculosis vaccine.
Rather than directly poisoning cancer cells, BCG stimulates a powerful local immune response within the bladder.
For appropriately selected patients with high-risk non-muscle-invasive bladder cancer, BCG can substantially reduce recurrence and progression.
Treatment usually begins with an induction course of six weekly treatments, followed by maintenance treatment where appropriate.
What are the side effects of BCG?
Common effects include:
- urinary frequency
- urgency
- burning when passing urine
- mild haematuria
- flu-like symptoms
- mild fever
These symptoms may become more noticeable as treatment progresses.
Serious systemic BCG infection is rare, but significant or persistent fever, rigors or severe illness after treatment requires urgent medical assessment.
Why might I need another TURBT?
A second or re-staging TURBT may be recommended when:
- the original tumour was high-grade T1
- the first resection was incomplete
- adequate bladder muscle was not present in the pathology specimen
- there is concern that residual tumour remains
NICE recommends a further TURBT within six weeks when the first TURBT demonstrates high-risk non-muscle-invasive bladder cancer.
This matters because the repeat procedure can occasionally identify more extensive disease than was apparent initially.
What happens if BCG does not work?
Persistent or recurrent high-grade cancer despite adequate BCG is known as BCG-unresponsive disease in defined circumstances.
At this stage, the risk of progression increases.
For patients who are fit for surgery, radical cystectomy remains an important standard treatment option.
For patients who cannot undergo cystectomy, or who choose not to, selected bladder-preserving treatments and clinical trials may be considered through a specialist bladder cancer multidisciplinary team.
This is an area in which treatment is evolving rapidly.
Muscle-invasive bladder cancer
Muscle-invasive bladder cancer means the cancer has grown into the muscular wall of the bladder.
It requires more intensive treatment but can still frequently be treated with curative intent.
Further staging usually includes CT imaging of the chest, abdomen and pelvis to look for lymph-node or distant spread.
MRI can also help assess local tumour extent in selected patients.
A specialist multidisciplinary team should discuss treatment.
How is muscle-invasive bladder cancer treated?
For potentially curable muscle-invasive bladder cancer, the two principal approaches are:
Systemic treatment followed by radical cystectomy
or
Bladder-preserving chemoradiotherapy
The best approach depends on the tumour, the patient’s general health and kidney function, anatomy, bladder function and personal preferences.
Peri-operative chemotherapy and immunotherapy
Systemic treatment before surgery has long formed an important part of treatment for suitable patients with muscle-invasive bladder cancer.
Traditionally this has involved cisplatin-based chemotherapy, such as gemcitabine with cisplatin.
The pathway changed further in 2026.
NICE now recommends durvalumab with gemcitabine and cisplatin before surgery, followed by durvalumab after surgery, as an option within its marketing authorisation for adults with muscle-invasive bladder cancer.
Durvalumab is an immune checkpoint inhibitor.
The 2026 European Association of Urology guidelines similarly recommend peri-operative gemcitabine/cisplatin plus durvalumab for suitable cisplatin-eligible patients with operable muscle-invasive disease.
Not every patient is suitable for cisplatin or immunotherapy.
Clinicians consider kidney function, hearing, general fitness, cardiac health, and other medical conditions before recommending treatment.
What is radical cystectomy?
Radical cystectomy means surgical removal of the bladder together with pelvic lymph nodes.
In men, surgery commonly also involves the prostate and seminal vesicles.
In women, surgery may involve adjacent reproductive organs depending upon tumour location and whether an organ-preserving approach is oncologically appropriate.
Radical cystectomy can be performed using:
- open surgery
- robot-assisted keyhole surgery
It remains major cancer surgery whichever technique is used.
Where radical cystectomy is required, treatment planning and surgery should take place through an experienced specialist bladder cancer MDT.
What happens to urine after the bladder is removed?
A new route for storing or passing urine must be created.
This is called urinary diversion.
Several options exist.
Ileal conduit
A short segment of small bowel is used to connect the ureters to a small opening—or stoma—on the abdominal wall.
Urine drains continuously into a discreet external bag.
This is the commonest and often the simplest urinary diversion.
Orthotopic neobladder
A reservoir is constructed using bowel and connected to the urethra.
This allows urine to continue to be passed through the natural urinary channel.
A neobladder is not appropriate for everyone.
Patients need to understand that:
- continence takes time to develop
- night-time leakage is relatively common initially
- some patients need intermittent self-catheterisation
- kidney function and tumour location influence suitability
Continent catheterisable reservoir
A reservoir is made internally and emptied by passing a catheter through a small abdominal opening.
There is no external urinary bag, but reliable self-catheterisation is required.
No single urinary diversion is best for everybody.
The correct decision depends on the cancer, kidney function, lifestyle, manual dexterity and what matters most to the individual patient.
Can muscle-invasive bladder cancer be treated without removing the bladder?
Yes, in appropriately selected patients.
A bladder-preserving approach known as trimodal therapy combines:
- maximal TURBT
- radiotherapy
- medication to make the cancer more sensitive to radiotherapy
The best candidates generally have a tumour that can be adequately resected, good bladder function, and no features that make successful bladder preservation unlikely.
Patients need ongoing cystoscopic surveillance afterwards.
Occasionally, salvage cystectomy is required if invasive cancer returns.
Trimodal therapy should not simply be regarded as a lesser treatment for patients who are unfit for surgery.
For appropriately selected patients, it represents a genuine curative treatment strategy that should be discussed alongside radical cystectomy.
Treatment after cystectomy
The need for additional treatment after surgery depends on:
- the final pathological stage
- lymph-node involvement
- treatments already received
- tumour biomarkers
- general health
For selected patients at high risk of recurrence after surgery, further systemic treatment may be considered.
The introduction of peri-operative durvalumab means this area of treatment is continuing to evolve.
Advanced and metastatic bladder cancer
The systemic treatment of advanced urothelial cancer has changed dramatically.
Treatment may include:
- immunotherapy
- chemotherapy
- antibody-drug conjugates
- targeted treatments selected according to tumour genetics
One important advance has been the combination of enfortumab vedotin and pembrolizumab.
Enfortumab vedotin is an antibody-drug conjugate that targets a protein called nectin-4, while pembrolizumab is an immune checkpoint inhibitor.
Some bladder cancers also contain alterations in the FGFR3 gene.
For appropriate patients with unresectable or metastatic urothelial cancer containing an FGFR3 alteration following previous PD-1 or PD-L1 treatment, NICE has recommended the targeted treatment erdafitinib.
This is an important example of precision medicine in bladder cancer, where the tumour’s molecular characteristics can directly influence treatment.
Because treatments and funding pathways in advanced bladder cancer are changing rapidly, recommendations should always be discussed with a specialist uro-oncology team.
Follow-up after bladder cancer treatment
Bladder cancer differs from many cancers because recurrence within the remaining urothelium is common.
For this reason, follow-up can continue for many years.
After non-muscle-invasive bladder cancer, surveillance commonly involves:
- flexible cystoscopy
- urine testing in selected circumstances
- periodic imaging in higher-risk patients
The frequency depends on the original cancer’s risk category.
Low-risk tumours require substantially less surveillance than high-risk T1 cancer or carcinoma in situ.
Patients with high-risk disease may require lifelong follow-up.
After radical cystectomy, surveillance may include:
- CT imaging
- kidney-function testing
- metabolic blood tests
- assessment of urinary diversion
- vitamin B12 monitoring where relevant
Patients treated with bladder-preserving chemoradiotherapy continue to require cystoscopic examination of the preserved bladder.
Can bladder cancer come back?
Yes. Recurrence is common, particularly with non-muscle-invasive bladder cancer.
This does not necessarily mean that the original treatment failed.
The entire urothelial lining may remain susceptible to forming additional tumours.
A useful way of thinking about bladder cancer is therefore not simply as one abnormal growth, but as a disease involving a lining that may remain at risk.
This is why scheduled surveillance is so important.
Early recurrence can often be identified and treated before it becomes more serious.
What is the outlook for bladder cancer?
The outlook depends primarily on:
- stage
- grade
- lymph-node involvement
- tumour biology
- response to treatment
- general health
Patients with small low-grade non-muscle-invasive tumours generally have an excellent cancer-specific outlook, although repeated treatments and surveillance may be required because of recurrence.
High-risk non-muscle-invasive disease carries a greater risk of progression and therefore requires more intensive treatment.
Muscle-invasive disease is more serious, but many patients can still be treated with curative intent using systemic therapy followed by surgery or bladder-preserving chemoradiotherapy.
Advanced metastatic disease is generally not regarded as curable, but newer systemic treatments have substantially changed the treatment landscape.
Population statistics cannot accurately predict what will happen to an individual patient.
A personalised prognosis should be based on the complete pathology, staging investigations, overall fitness and response to treatment.
Can bladder cancer be prevented?
Not every case can be prevented.
The single most important modifiable risk factor is smoking.
If you smoke, stopping reduces your exposure to the carcinogens associated with bladder cancer and brings numerous additional health benefits.
Occupational safety precautions are also important for people working with potentially carcinogenic industrial chemicals.
There is currently no national UK screening programme for bladder cancer.
The practical priority is therefore recognition of symptoms.
Do not ignore blood in the urine. Early diagnosis gives the greatest opportunity to treat bladder cancer before it becomes more advanced.
Frequently asked questions about bladder cancer
Is bladder cancer curable?
Yes. Many bladder cancers are curable, particularly when diagnosed before they have spread. Most bladder cancers are non-muscle-invasive at diagnosis and can often be managed without removing the bladder. Muscle-invasive disease is more serious but may still be treated with curative intent using surgery or bladder-preserving chemoradiotherapy.
Does blood in the urine always mean bladder cancer?
No. Blood in the urine can be caused by infection, kidney stones, an enlarged prostate and several other conditions. However, bladder and kidney cancers are important causes that must be excluded, particularly when haematuria is visible and painless.
I saw blood once, and it went away. Do I still need to see a doctor?
Yes. Bladder tumours frequently bleed intermittently. Having normal urine afterwards does not exclude bladder cancer, so a single unexplained episode of visible haematuria should be assessed.
What is the first test for bladder cancer?
Most patients with suspected bladder cancer undergo flexible cystoscopy, together with urine testing and appropriate imaging of the kidneys and urinary tract. If cystoscopy identifies a tumour, TURBT is then used to remove it and obtain tissue for pathological diagnosis.
Is cystoscopy painful?
Flexible cystoscopy is performed using local anaesthetic gel and generally takes only a few minutes. Most patients describe brief discomfort or pressure rather than significant pain. Mild burning when passing urine can occur briefly afterwards.
What is TURBT?
TURBT stands for transurethral resection of bladder tumour. A telescope is passed through the urethra while the patient is under anaesthesia, allowing the tumour to be removed without an external incision. The tissue is then examined to determine the cancer’s type, grade and stage.
What does non-muscle-invasive bladder cancer mean?
It means the tumour has not grown into the muscular wall of the bladder. It includes Ta, T1 and carcinoma in situ. Treatment usually begins with TURBT and may be followed by intravesical chemotherapy or BCG depending on the risk of recurrence and progression.
Why is BCG used for bladder cancer?
BCG is an immunotherapy placed directly into the bladder. It stimulates the immune system to attack remaining high-grade cancer cells and is an important treatment for high-risk non-muscle-invasive bladder cancer.
Will I definitely need my bladder removed?
No. Most people diagnosed with bladder cancer do not require immediate bladder removal. Radical cystectomy is mainly considered for muscle-invasive disease and selected very-high-risk or BCG-unresponsive non-muscle-invasive cancers.
Can bladder cancer be treated without removing the bladder?
Yes. Non-muscle-invasive bladder cancer is usually treated while preserving the bladder. Even some muscle-invasive cancers can be treated with a combination of maximal TURBT, radiotherapy and radiosensitising treatment known as trimodal therapy.
Can bladder cancer return after treatment?
Yes. Bladder cancer has a significant tendency to recur, particularly when it remains non-muscle-invasive. This is why patients undergo scheduled cystoscopic surveillance after treatment.
Does stopping smoking still help after a bladder cancer diagnosis?
Yes. Stopping smoking removes continued exposure to one of the major carcinogenic influences associated with bladder cancer and provides important general health benefits. Smoking cessation should form part of ongoing care.
When should you see a urologist?
Arrange urological assessment if you have:
- visible blood in the urine — even once
- unexplained microscopic blood on repeated urine testing
- repeated urinary symptoms without proven infection
- persistent urinary frequency or urgency
- recurrent urinary infections associated with haematuria
- an abnormal bladder or urinary-tract scan
- a diagnosis of bladder cancer and would like further explanation or a second opinion
Do not wait for haematuria to happen a second time before seeking advice.
Private bladder cancer and haematuria assessment
I am Mr Neil Haldar, Consultant Urological Surgeon, with more than 20 years’ experience in urology and a specialist interest in uro-oncology.
I assess patients with:
- visible and non-visible haematuria
- suspected bladder cancer
- abnormal cystoscopy or imaging findings
- newly diagnosed bladder tumours
- non-muscle-invasive bladder cancer
- recurrent bladder cancer
- complex treatment decisions
- requests for a second opinion
Investigation can include urine and blood testing, imaging and flexible cystoscopy, with onward treatment arranged according to the findings and specialist multidisciplinary-team recommendations.
Concerned about blood in your urine?
Don’t ignore blood in your urine—even if it happened only once and has now stopped.
If you would like a private urological assessment, bladder cancer consultation or second opinion, you can arrange an appointment with Mr Neil Haldar.
Private consultations are available across Buckinghamshire, Berkshire and London.
About the author
Mr Neil Haldar MBBS MD FRCS (Eng) FRCS (Urol) is a Consultant Urological Surgeon specialising in uro-oncology, robotic and minimally invasive surgery and general urology.
This article is intended for general information and does not replace individual medical advice. If you develop visible blood in the urine or other concerning symptoms, please seek appropriate medical assessment.
Last medically reviewed: August 2026
Next review: August 2027, or earlier if major bladder-cancer guidance changes.
Mr Neil Haldar is a UK Consultant Urological Surgeon specialising in prostate cancer, robotic surgery, uro-oncology and paediatric urology. He offers expert diagnosis, treatment and second opinions for complex urological conditions.